| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | PANTOPRAZOLE SODIUM | 2 | |
| Methacrylic Acid - Ethyl Acrylate Copolymer (1:1) Type A | INACTIVE INGREDIENT | NX76LV5T8J | PANTOPRAZOLE SODIUM | 5 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Diclofenac Sodium and Misoprostol Delayed-Release Tablets | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Diclofenac Sodium Delayed-release Tablets USP, 25 mg, 50 mg and 75 mg | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Diclofenac Sodium Delayed-release Tablets USP, 25 mg, 50 mg and 75 mg | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | DIVALPROEX SODIUM | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | BUPROPION HYDROCHLORIDE | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Naproxen Delayed-release Tablets USP, 375 mg and 500 mg | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use PANTOPRAZOLE sodium delayed-release tablets, USP safely and effectively. See full prescribing information for PANTOPRAZOLE sodium delayed-release tablets, USP. PANTOPRAZOLE sodium delayed-release tablets, USP, for oral administration Initial U.S. approval: 2000 | 11 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use OMEPRAZOLE delayed-release capsules, USP safely and effectively. See full prescribing information for OMEPRAZOLE delayed-release capsules, USP. OMEPRAZOLE Delayed-Release Capsules, USP, for oral use INITIAL U.S. APPROVAL: 1989 | 4 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use bupropion hydrochloride extended-release tablets (XL) safely and effectively. See full prescribing information for bupropion hydrochloride extended-release tablets (XL). Bupropion Hydrochloride Extended-Release Tablets, USP (XL) for oral use Initial U.S. Approval: 1985 | 3 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use OMEPRAZOLE delayed-release capsules, USP safely and effectively. See full prescribing information for OMEPRAZOLE delayed-release capsules, USP. OMEPRAZOLE Delayed-Release Capsules, USP, for oral use INITIAL U.S. APPROVAL: 1989 | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use esomeprazole magnesium delayed-release capsules USP safely and effectively. See full prescribing information for esomeprazole magnesium delayed-release capsules USP. ESOMEPRAZOLE MAGNESIUM delayed-release capsules USP, for oral use Initial U.S. Approval: 1989 (omeprazole) | 2 | |
| methacrylic acid - ethyl acrylate copolymer (1:1) type A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use omeprazole safely and effectively. See full prescribing information for omeprazole. OMEPRAZOLE delayed-release capsules USP, for oral use INITIAL U.S. APPROVAL: 1989 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use pantoprazole sodium delayed-release tablets safely and effectively. See full prescribing information for pantoprazole sodium delayed-release tablets. PANTOPRAZOLE sodium delayed-release tablets USP, for oral administration Initial U.S. approval: 2000 | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use pantoprazole sodium delayed-release tablets USP safely and effectively. See full prescribing information for pantoprazole sodium delayed-release tablets USP. PANTOPRAZOLE Sodium delayed-release tablets USP for oral use Initial U.S. approval: 2000 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use OMEPRAZOLE delayed-release capsules, USP safely and effectively. See full prescribing information for OMEPRAZOLE delayed-release capsules, USP . OMEPRAZOLE Delayed-Release Capsules, USP , for oral use INITIAL U.S. APPROVAL: 1989 | 15 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use DIVALPROEX Sodium Delayed-Release Tablets, USP safely and effectively. See full prescribing information for DIVALPROEX Sodium Delayed-Release Tablets, USP DIVALPROEX Sodium Delayed-Release Tablets, USP for Oral use Initial U.S. Approval: 1983 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use divalproex sodium delayed-release tablets, USP safely and effectively. See full prescribing information for divalproex sodium delayed-release tablets, USP. DIVALPROEX sodium delayed-release tablets, USP for oral use Initial U.S. Approval: 1983 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use Divalproex Sodium Delayed Release Tablets safely and effectively. See full prescribing information for Divalproex Sodium Delayed Release Tablets. Divalproex Sodium Delayed Release Tablets USP for Oral use. Initial U.S. Approval: 1983 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use Pantoprazole Sodium Delayed-Release Tablets USP safely and effectively. See full prescribing information for Pantoprazole Sodium Delayed-Release Tablets USP. PANTOPRAZOLE Sodium Delayed-Release Tablets USP for oral use Initial U.S. Approval: 2000 | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use OMEPRAZOLE delayed-release capsules, USP safely and effectively. See full prescribing information for OMEPRAZOLE delayed-release capsules, USP . OMEPRAZOLE Delayed-Release Capsules, USP , for oral use INITIAL U.S. APPROVAL: 1989 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use omeprazole safely and effectively. See full prescribing information for omeprazole. OMEPRAZOLE DELAYED-RELEASE CAPSULES, USP INITIAL U.S. APPROVAL: 1989 | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use duloxetine delayed-release capsules, USP safely and effectively. See full prescribing information for duloxetine delayed-release capsules, USP. DULOXETINE delayed-release capsules USP, for oral use. Initial U.S. Approval: 2004 | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Enteric Coated Aspirin Regular Strength | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use pantoprazole sodium safely and effectively. See full prescribing information for pantoprazole sodium delayed-release tablets. Pantoprazole Sodium Delayed-Release Tablets, USP Initial U.S. approval: 2000 | 1 | |
| methacrylic acid - ethyl acrylate copolymer (1:1) type a | INACTIVE INGREDIENT | NX76LV5T8J | Diclofenac sodium and misoprostol delayed-release tablets | 3 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use divalproex sodium extended-release tablets USP safely and effectively. See full prescribing information for divalproex sodium extended-release tablets USP. DIVALPROEX Sodium Extended-Release Tablets USP, for Oral Use Initial U.S. Approval: 2000 | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use Duloxetine Delayed-release Capsules safely and effectively. See full prescribing information for Duloxetine Delayed-release Capsules. DULOXETINE delayed-release capsules USP for oral use. Initial U.S. Approval: 2004 | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use Pantoprazole Sodium Delayed-Release Tablets safely and effectively. See full prescribing information for Pantoprazole Sodium Delayed-Release Tablets. PANTOPRAZOLE SODIUM delayed-release tablets Initial U.S. approval: 2000 | 3 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use safely and effectively. See full prescribing information for . Initial U.S. Approval: 1997 budesonide capsules (enteric coated) budesonide capsules (enteric coated) BUDESONIDE capsules (enteric coated), for oral use | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Divalproex Sodium Delayed Release Tablets USP | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use omeprazole safely and effectively. See full prescribing information for omeprazole. OMEPRAZOLE DELAYED-RELEASE CAPSULES, USP Initial U.S. Approval: 1989 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | NAPROXEN DELAYED-RELEASE TABLETS USP 1005 1006 Rx only | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Venlafaxine Hydrochloride Extended-Release Capsules Rx only | 3 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use lansoprazole delayed-release capsules safely and effectively. See full prescribing information for: LANSOPRAZOLE delayed-release capsules USP For oral administration Initial U.S. Approval: 1995 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use Omeprazole safely and effectively. See full prescribing information for Omeprazole. Omeprazole (Omeprazole) CAPSULE for ORAL use. Initial U.S. Approval: 2013 | 3 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM. PANTOPRAZOLE SODIUM (PANTOPRAZOLE SODIUM) TABLET for ORAL use. Initial U.S. Approval: 2007 | 3 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | DIVALPROEX SODIUM DELAYED-RELEASE TABLETS | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Bupropion Hydrochloride Extended-Release Tablets USP (XL) | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | DRUG FACTS | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Drug Facts | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | FERROUS SULFATE ENTERIC-COATED TABLETS | 3 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Unknown Title | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use metoprolol succinate extended-release tablets safely and effectively. See full prescribing information for metoprolol succinate extended-release tablets. Metoprolol Succinate Extended-Release Tablets, USP for Oral Use INITIAL U.S. APPROVAL: 1992 | 5 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Diclofenac Sodium Delayed-release Tablets USP, 25 mg, 50 mg and 75 mg | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use omeprazole safely and effectively. See full prescribing information for omeprazole. OMEPRAZOLE DELAYED-RELEASE CAPSULES, USP INITIAL U.S. APPROVAL: 1989 | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use tamsulosin hydrochloride safely and effectively. See full prescribing information for tamsulosin hydrochloride capsules. Tamsulosin Hydrochloride Capsules USP, 0.4 mg Initial U.S. Approval: 1997 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | DRUG FACTS | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Aspirin EC Tablets, 81 mg | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | PRESCRIBING INFORMATION BuPROPion Hydrochloride Extended-Release Tablets (XL) | 3 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use PREMPRO/PREMPHASE safely and effectively. See full prescribing information for PREMPRO/PREMPHASE. PREMPRO ® (conjugated estrogens/medroxyprogesterone acetate tablets) PREMPHASE ® (conjugated estrogens plus medroxyprogesterone acetate tablets) Initial U.S. Approval: 1995 | 3 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Diclofenac Sodium Delayed-release Tablets, USP | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | FERROUS SULFATE ENTERIC-COATED TABLETS | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use PREMPRO/PREMPHASE safely and effectively. See full prescribing information for PREMPRO/PREMPHASE. PREMPRO ® (conjugated estrogens/medroxyprogesterone acetate tablets) PREMPHASE ® (conjugated estrogens plus medroxyprogesterone acetate tablets) Initial U.S. Approval: 1995 | 3 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use tamsulosin hydrochloride safely and effectively. See full prescribing information for tamsulosin hydrochloride capsules. Tamsulosin Hydrochloride Capsules USP, 0.4 mg Initial U.S. Approval: 1997 | 2 | |
| methacrylic acid - ethyl acrylate copolymer (1:1) Type A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use lansoprazole delayed-release capsules safely and effectively. See full prescribing information for: LANSOPRAZOLE delayed-release capsules USP For oral administration Initial U.S. Approval: 1995 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use omeprazole safely and effectively. See full prescribing information for omeprazole. OMEPRAZOLE DELAYED-RELEASE CAPSULES, USP Initial U.S. Approval: 1989 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Drug Facts | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use lamotrigine extended-release tablets safely and effectively. See full prescribing information for lamotrigine extended-release tablets. Lamotrigine Extended-Release Tablets Initial U.S. Approval: 1994 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | WELLBUTRIN XL ® (bupropion hydrochloride extended-release tablets) | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Drug Facts | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | NAPROXEN DELAYED-RELEASE TABLETS USP 1006 Rx only | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use tamsulosin hydrochloride capsules USP safely and effectively. See full prescribing information for tamsulosin hydrochloride capsules USP. TAMSULOSIN HYDROCHLORIDE capsules USP for oral use Initial U.S. Approval: 1997 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Ecotrin Low Strength | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Diclofenac Sodium Delayed-release Tablets, USP 50 mg | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use lansoprazole delayed-release capsules USP safely and effectively. See full prescribing information for lansoprazole delayed-release capsules USP. LANSOPRAZOLE delayed-release capsules USP for oral use Initial U.S. Approval: 1995 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Diclofenac Sodium Delayed-release Tablets USP, 25 mg, 50 mg and 75 mg | 3 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Omeprazole Delayed-Release Capsules These highlights do not include all the information needed to use. See full prescribing information for. Initial U.S. Approval: | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Omeprazole Delayed-Release Capsules These highlights do not include all the information needed to use. See full prescribing information for. Initial U.S. Approval: | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Drug Facts | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | DRUG FACTS | 1 | |
| Methacrylic Acid - Ethyl Acrylate Copolymer (1:1) Type A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use DEXILANT safely and effectively. See full prescribing information for DEXILANT. DEXILANT (dexlansoprazole) delayed-release capsules, for oral use Initial U.S. Approval: 1995 (lansoprazole) | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Naproxen Delayed-release Tablets USP, 375 mg and 500 mg | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use pantoprazole sodium safely and effectively. See full prescribing information for pantoprazole sodium delayed-release tablets. Pantoprazole Sodium Delayed-Release Tablets, USP Initial U.S. approval: 2000 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use lansoprazole delayed-release capsules USP safely and effectively. See full prescribing information for lansoprazole delayed-release capsules USP. LANSOPRAZOLE delayed-release capsules USP for oral use Initial U.S. Approval: 1995 | 4 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use pantoprazole sodium delayed-release tablets USP safely and effectively. See full prescribing information for pantoprazole sodium delayed-release tablets USP. PANTOPRAZOLE sodium delayed-release tablets USP for oral use Initial U.S. Approval: 2000 | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Omeprazole Delayed-Release Capsules These highlights do not include all the information needed to use See full prescribing information for use INITIAL U.S. APPROVAL: 2007 | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Diclofenac Sodium Delayed-release Tablets USP, 25 mg, 50 mg and 75 mg | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use Lansoprazole Delayed-Release Capsules and Lansoprazole Delayed-Release Orally Disintegrating Tablets safely and effectively. See full prescribing information for: Lansoprazole Delayed-Release Capsules Lansoprazole Delayed-Release Orally Disintegrating Tablets For oral administration Initial U.S. Approval: 1995 | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | NAPROXEN DELAYED-RELEASE TABLETS USP 1005 1006 Rx only | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use tamsulosin hydrochloride capsules safely and effectively. See full prescribing information for tamsulosin hydrochloride capsules. Tamsulosin Hydrochloride Capsules, 0.4 mg Initial U.S. Approval: 1997 | 3 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Bisacodyl USP 5 mg Laxative | 3 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | PAXIL CR ® (paroxetine hydrochloride) Controlled-Release Tablets | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use PROTONIX safely and effectively. See full prescribing information for PROTONIX. PROTONIX (pantoprazole sodium) delayed-release tablets PROTONIX (pantoprazole sodium) for delayed-release oral suspension Initial U.S. approval: 2000 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | 21b3b8a2-bfed-4945-954d-6a42ea61888f | 3 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | ASPIRIN ENTERIC COATED ORANGE TABLETS, 325 mg | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | ASPIRIN ENTERIC COATED YELLOW TABLETS, 81 mg | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Divalproex Sodium Delayed-Release Tablets, USP Rx only | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use pantoprazole sodium delayed-release tablets, USP safely and effectively. See full prescribing information for pantoprazole sodium delayed-release tablets, USP. Pantoprazole Sodium Delayed-Release Tablets, USP Initial U.S. approval: 2000 | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | NAPROXEN DELAYED-RELEASE TABLETS Rx only | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Omeprazole 20 mg | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Aspirin 81 mg Pain reliever | 3 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use pantoprazole sodium delayed-release tablets USP safely and effectively. See full prescribing information for pantoprazole sodium delayed-release tablets USP. PANTOPRAZOLE sodium delayed-release tablets USP for oral use Initial U.S. Approval: 2000 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use PROTONIX safely and effectively. See full prescribing information for PROTONIX. PROTONIX (pantoprazole sodium) delayed-release tablets PROTONIX (pantoprazole sodium) for delayed-release oral suspension Initial U.S. approval: 2000 | 1 | |
| methacrylic acid - ethyl acrylate copolymer (1:1) type a | INACTIVE INGREDIENT | NX76LV5T8J | WELLBUTRIN XL ® (bupropion hydrochloride extended-release tablets) | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | PAXIL CR ® (paroxetine hydrochloride) Controlled-Release Tablets | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use lansoprazole delayed-release orally disintegrating tablets safely and effectively. See full prescribing information for lansoprazole delayed-release orally disintegrating tablets. LANSOPRAZOLE delayed-release orally disintegrating tablets for oral use Initial U.S. Approval: 1995 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Drug Facts | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Aspirin Low Tablets | 1 | |
| methacrylic acid - ethyl acrylate copolymer (1:1) type a | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use Lansoprazole Delayed-Release Capsules safely and effectively. See full prescribing information for: Lansoprazole Delayed-Release Capsules For oral administration Initial U.S. Approval: 1995 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | PRESCRIBING INFORMATION BuPROPion Hydrochloride Extended-Release Tablets (XL) Revised: August 2010 Rx only 174662-3 | 1 | |
| methacrylic acid - ethyl acrylate copolymer (1:1) type A | INACTIVE INGREDIENT | NX76LV5T8J | Divalproex Sodium Delayed-Release Tablets, USP | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use Pantoprazole Sodium Delayed-Release Tablets safely and effectively. See full prescribing information for Pantoprazole Sodium Delayed-Release Tablets. PANTOPRAZOLE SODIUM delayed-release tablets Initial U.S. approval: 2000 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | 6ce1d9b9-3a71-4c10-9c09-6259088baafb | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Diclofenac Sodium Delayed-release Tablets, USP 75 mg | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | Glipizide Extended-Release Tablets Rx only | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | WELLBUTRIN XL ® (bupropion hydrochloride extended-release tablets) | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | 9fb17714-bdb1-4bfa-bc04-d9c011604cde | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | f738ddad-fef0-43cb-b791-b046fdcec311 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use Omeprazole Delayed-Release Capsules safely and effectively. See full prescribing information for Omeprazole Delayed-Release Capsules. Initial U.S. Approval: 2002 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use Ranexa safely and effectively. See full prescribing information for Ranexa. Ranexa (ranolazine) extended-release tablets Initial U.S. Approval: 2006 | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | DIVALPROEX SODIUM DELAYED-RELEASE TABLETS | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | PREVPAC ® (lansoprazole 30 mg capsules, amoxicillin 500 mg capsules, USP, and clarithromycin 500 mg tablets, USP) | 2 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | DIVALPROEX SODIUM DELAYED-RELEASE TABLETS | 4 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use Flomax safely and effectively. See full prescribing information for Flomax. Flomax ® (tamsulosin hydrochloride) Capsules, 0.4 mg Initial U.S. Approval: 1997 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | 4e954825-3f60-4dbb-a1be-b146fe1acae4 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use Flomax safely and effectively. See full prescribing information for Flomax. Flomax ® (tamsulosin hydrochloride) Capsules, 0.4 mg Initial U.S. Approval: 1997 | 1 | |
| METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use Omeprazole Delayed-Release Capsules safely and effectively. See full prescribing information for Omeprazole Delayed-Release Capsules. Initial U.S. Approval: 2002 | 1 | |
| methacrylic acid - ethyl acrylate copolymer (1:1) type A | INACTIVE INGREDIENT | NX76LV5T8J | These highlights do not include all the information needed to use PREVACID safely and effectively. See full prescribing information for: PREVACID (lansoprazole) Delayed-Release Capsules PREVACID SoluTab (lansoprazole) Delayed-Release Orally Disintegrating Tablets For oral administration Initial U.S. Approval: 1995 | 2 | |